Based on the invasive pneumococcal isolates referred to reference laboratories in Scotland in
1988–99, we identified the distribution of serotypes/groups and their antimicrobial resistance
patterns in order to evaluate the coverage of polysaccharide and the new pneumococcal
conjugate vaccines. A total of 5659 invasive isolates were included. Of these, 5124 (90·5%)
were blood isolates, 308 (5·5%) were CSF isolates, 143 (2·5%) were blood and CSF and 84
(1·5%) were other normally sterile isolates. The most prevalent 11 serotypes/groups were 14, 9,
19, 6, 23, 1, 3, 4, 7, 8 and 18, in numerical order. These accounted for 84% of total
serotypes/groups.
The serotypes/groups included in the 23 and 14-valent polysaccharide vaccines accounted for
96% and 88% of all isolates. Both vaccines accounted for 98% of penicillin non-susceptible
and 100% of erythromycin non-susceptible isolates. The 7, 9, and 11-valent conjugate vaccines
covered 61, 68 and 80% of invasive isolates respectively. The coverage of these vaccines was
substantially higher in youngest age group with 84, 86 and 93% of invasive isolates in children
< 2 years included in the 7, 9 and 11-valent conjugate vaccines compared with 58, 64 and 77%
in adults [ges ] 65 years of age.
The serotype/group distribution of invasive isolates in Scotland varied from year to year
over the period 1993–9. The coverage of the 23-valent vaccine remained above 95% in each
year but the coverage of the 7, 9 and 11-valent conjugate vaccines showed more marked
fluctuation with coverage as low as 53, 60 and 75% in some years. Continued surveillance of
invasive pneumococcal isolates is required to inform the development of appropriate vaccine
strategies to prevent pneumococcal disease in Scotland.